Quick Answer
ArriVent BioPharma, Inc. reported Cash and Equivalents of $45.54 million for fiscal year 2025.
ArriVent BioPharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $45.54M | -38.7% |
| 2024 | $74.29M | -50.6% |
| 2023 | $150.39M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $112.67M | -60.2% | -0.1% |
| June 30, 2025 | $112.77M | -62.2% | +126.1% |
| March 31, 2025 | $49.87M | -84.3% | -32.9% |
| December 31, 2024 | $74.29M | -50.6% | -73.7% |
| September 30, 2024 | $282.86M | — | -5.3% |
| June 30, 2024 | $298.67M | — | -5.9% |
| March 31, 2024 | $317.39M | — | +111.0% |
| December 31, 2023 | $150.39M | — | — |
- ArriVent BioPharma, Inc. showed a decrease of -38.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, ArriVent BioPharma, Inc.’s cash and equivalents has declined by 69.7% (from $150.39 million to $45.54 million).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: